Zymeworks appoints two to its board of directors
Dr. Hillan is the CEO of Achaogen Inc. He has served as CEO and a member of the board of directors of Achaogen since October 2011.
Prior to joining Achaogen, Dr. Hillan worked at Genentech Inc., a pharmaceutical company and a member of the Roche Group. Dr. Hillan worked in progressively senior roles after joining Genentech in 1994.
He was responsible for numerous successful drug approvals and led the medical and scientific strategies for Genentech’s immunology, tissue growth and repair drug portfolio.
He also served on the board of directors of Relypsa Inc., a publicly traded biotechnology company that was acquired in 2016 by Galencia AG.
Dr. Hillan has an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow in the United Kingdom. He is a Fellow of the Royal College of Surgeons, and a Fellow of the Royal College of Pathologists.
Dr. Hillan has authored dozens of scientific publications and is a named inventor on approximately 50 issued patents.
Mr. Renton served as CEO and President of Onyx Pharmaceuticals, Inc. from 1993 to 2008 and was the chairperson of the board of directors of Onyx from 2000 to 2008. Onyx was acquired by Amgen Inc. in 2013.
Before joining Onyx, he was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983 prior to its acquisition by Chiron in 1991.
He currently serves as chairperson of the board of directors of Portola Pharmaceuticals Inc. and on the board of directors of AnaptysBio Inc.
Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University.
Concurrent with the appointment of Dr. Hillan and Mr. Renton, Zymeworks also announces that Dr. Donald Drakeman has retired from the Company’s board of directors, and is transitioning to the position of special advisor to Zymeworks and the board of directors. ■
LATEST MOVES FROM British Columbia
- Napier Ventures director and CFO Michael Raftery resigns
- Group Ten Metals appoints Tim Thiessen as CFO
- Cardiome Pharma appoints Justin Renz as CFO
- Apivio Systems appoints two to board
- Nevsun Resources appoints Peter G. Kukielski as CEO
More inside POST